AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
AMENDMENT NO. 9
ProPhase Labs, Inc.
(Name of Issuer)
Common Stock, par value $0.0005 per share
(Title of Class of Securities)
74345W 10 8
Herbert Kozlov, Esq.
Reed Smith LLP
599 Lexington Avenue
New York, New York 10022
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
September 29, 2017
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ]
CUSIP No: 74345W 10 8
|1.||NAME OF REPORTING PERSON:|
|2.||CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP|
|(a) [ ]|
|(b) [ ]|
|3.||SEC USE ONLY|
|4.||SOURCE OF FUNDS (See Instructions)||PF|
|5.||CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e):||[ ]|
|6.||CITIZENSHIP OR PLACE OF ORGANIZATION||United States|
|7.||SOLE VOTING POWER||3,009,638 (1)|
|8.||SHARED VOTING POWER||0|
|9.||SOLE DISPOSITIVE POWER||3,009,638 (1)|
|10.||SHARED DISPOSITIVE POWER||0|
|11.||AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON|
|3,009,638 shares of common stock (1)|
|12.||CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)||[ ]|
|13.||PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)||22.9% (2)|
|14.||TYPE OF REPORTING PERSON (See Instructions)||IN|
(1) Includes 700,000 shares of common stock issuable to the Reporting Person upon the exercise of stock options, which are vested and exercisable within the next 60 days.
(2) Based on 12,428,461 shares of common stock outstanding on October 2, 2017, plus 700,000 shares of Common Stock issuable to the Reporting Person upon the exercise of stock options, which are vested and exercisable within the next 60 days.
This Amendment No. 9 amends and supplements the Statement on Schedule 13D filed by Ted Karkus (the “Reporting Person”) on April 27, 2011 (the “Original Schedule 13D”, as amended and supplemented by Amendment No. 1 to the Schedule 13D filed on November 15, 2011, Amendment No. 2 to the Schedule 13D filed on December 14, 2011, Amendment No. 3 to the Schedule 13D filed on May 18, 2012, Amendment No. 4 to the Schedule 13D filed on September 19, 2014, Amendment No. 5 to the Schedule 13D filed on May 27, 2015, Amendment No. 6 to the Schedule 13D filed on June 8, 2015, Amendment No. 7 to the Schedule 13D filed on January 6, 2017, Amendment No. 8 to the Schedule 13D filed on May 3, 2017 and together with this Amendment No. 9, the “Schedule 13D”) to the extent specifically set forth below. Except as otherwise indicated, capitalized terms used herein and not defined herein have the meanings ascribed thereto in the Schedule 13D.
|Item 4.||Purpose of Transaction.|
Item 4 of the Schedule 13D is hereby amended by inserting the following:
On September 29, 2017, the Reporting Person tendered 364,950 shares of common stock to the Issuer in connection with the Issuer’s tender offer to purchase up to 4,000,000 shares of its common stock.
|Item 5.||Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.|
Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:
As of the date hereof, the Reporting Person is deemed to be the beneficial owner, within the meaning of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, of 3,009,638 shares of common stock of the Issuer, or approximately 22.9% of the Issuer’s shares outstanding, and also is deemed to have sole power to vote or direct the vote of, and sole power to dispose or direct the disposition of, such shares.
There have been no transactions in the securities of the Issuer effected by the Reporting Person in the last 60 days.
After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
|Dated: October 3, 2017|
|/s/ Ted Karkus|